A Phase 3 interventional study of Insulin degludec/liraglutide and Insulin degludec in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 36 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-14.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment, is one of 5 that started in 2017, is one of 49 in phase 3, and was the 53rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 720 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 55th largest by enrollment of the 428 interventional ones that give a count, is one of 17 that started in 2017, is one of 187 in phase 3, and was the 438th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia. The aim of this trial is to confirm the efficacy of insulin degludec/liraglutide in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral antidiabetic agents
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 720 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Insulin degludec/liraglutide
Drug: Insulin degludec
Drug: Liraglutide
Drug pages: Insulin degludec · Liraglutide
Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. For 26 weeks.
Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. For 26 weeks.
Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. For 26 weeks.
Change in HbA1c
Change in HbA1c from baseline (week 0) after 26 weeks of treatment is presented.
Time frame: Week 0, week 26
Change in Body Weight
Change in body weight from baseline (week 0) after 26 weeks of treatment is presented.
Time frame: Week 0, week 26
Number of Treatment Emergent Severe or BG Confirmed Hypoglycaemic Episodes
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification (requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or blood glucose (BG) confirmed by a plasma glucose (PG) value \< 3.1 millimoles per liter (mmol/L) with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. The number of episodes are represented as rates. The observed rates of treatment-emergent severe or BG confirmed hypoglycaemic episodes per patient years of exposure (PYE) (number of episodes divided by PYE multiplied by 100) during 26 weeks of treatment are presented.
Time frame: Weeks 0-26
Insulin Dose
The actual daily total insulin dose after 26 weeks of treatment is presented. This outcome measure is only applicable for Insulin degludec/liraglutide and Insulin degludec treatment arms.
Time frame: Week 26
Participants Who Achieved HbA1c < 7.0%, American Diabetes Association (ADA) Target (Yes/no)
Number of participants who achieved ADA HbA1c target (HbA1c \< 7.0%) (yes/no) after 26 weeks of treatment are presented.
Time frame: Week 26
Participants Who Achieved HbA1c ≤ 6.5%, International Diabetes Federation (IDF) Target (Yes/no)
Number of participants who achieved IDF HbA1c target (HbA1c ≤ 6.5%) (yes/no) after 26 weeks of treatment are presented.
Time frame: Week 26
Participants Who Achieved HbA1c <7.0% and Change in Body Weight From Baseline Below or Equal to Zero
Number of participants who achieved ADA HbA1c target (HbA1c \< 7.0%) (yes/no) and change from baseline in body weight below or equal to zero after 26 weeks are presented. Missing values are imputed by LOCF.
Time frame: Week 26
Participants Who Achieved HbA1c ≤ 6.5% and Change From Baseline in Body Weight Below or Equal to Zero
Number of participants who achieved IDF HbA1c target (HbA1c ≤ 6.5%) (yes/no) and change from baseline in body weight below or equal to zero after 26 weeks are presented. Missing values are imputed by LOCF.
Time frame: Week 26
Participants Who Achieved HbA1c < 7.0% Without Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of participants who achieved ADA HbA1c target (HbA1c \<7.0%) (yes/no) after 26 weeks of treatment and without severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment are presented. Missing values are imputed by LOCF.
Time frame: Week 26
Participants Who Achieved HbA1c ≤ 6.5% Without Severe or BG Confirmed Hypoglycaemic Episodes
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a PG value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of participants who achieved IDF HbA1c target (HbA1c ≤ 6.5%) (yes/no) after 26 weeks of treatment and without severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment are presented. Missing values are imputed by LOCF.
Time frame: Week 26
Participants Who Achieved HbA1c < 7.0% Without Severe or BG Confirmed Episodes, and Change From Baseline in Body Weight Below or Equal to Zero.
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a PG value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of participants who achieved ADA HbA1c target (HbA1c \< 7.0%) (yes/no) after 26 weeks of treatment without severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment and with change from baseline in body weight below or equal to zero are presented. Missing values are imputed by LOCF.
Time frame: Week 26
Participants Who Achieved HbA1c ≤ 6.5% Without Severe or BG Confirmed Episodes and Change From Baseline in Body Weight Below or Equal to Zero.
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a PG value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of participants who achieved IDF HbA1c target (HbA1c ≤ 6.5%) (yes/no) after 26 weeks of treatment without severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment and with change from baseline in body weight below or equal to zero are presented. Missing values are imputed by LOCF.
Time frame: Week 26
Change in Fasting Plasma Glucose (FPG)
Change from baseline (week 0) in FPG after 26 weeks of treatment is presented.
Time frame: Week 0, week 26
Change in Waist Circumferance
Change from baseline (week 0) in waist circumferance after 26 weeks of treatment is presented.
Time frame: Week 0, week 26
9-point SMPG Profile
Participants measured their PG levels using blood glucose meters at 9 time points (before breakfast, 90 minutes after the start of breakfast, before lunch, 90 minutes after the start of lunch, before dinner, 90 minutes after the start of dinner, at bedtime, at 4 am, before breakfast the following day). 9-point SMPG values at 26 weeks of treatment are presented.
Time frame: Week 26
Change in Mean of 9-point SMPG Profile
Participants measured their PG levels using blood glucose meters at 9 time points (before breakfast, 90 minutes after the start of breakfast, before lunch, 90 minutes after the start of lunch, before dinner, 90 minutes after the start of dinner, at bedtime, at 4 am, before breakfast the following day). The mean of profile is defined as the area under the profile divided by measurement time and is calculated using the trapezoidal method. Change in mean of the 9-point SMPG profile from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Mean Post-prandial Plasma Glucose (PG) Increments
Participants measured their PG levels using blood glucose meters at 9 time points (before breakfast, 90 minutes after the start of breakfast, before lunch, 90 minutes after the start of lunch, before dinner, 90 minutes after the start of dinner, at bedtime, at 4 am, before breakfast the following day). Post-prandial SMPG increments from before meal to 90 minutes after for breakfast, lunch and dinner were calculated. The mean increment over all meals was derived as the mean of all available meal increments. Change from baseline (week 0) in post-prandial SMPG increments for all meals after 26 weeks of treatment is presented.
Time frame: Week 0, week 26
Change in Fasting C-peptide - Ratio to Baseline
Change in fasting C-peptide (measured in nanomoles per liter \[nmol/L\]) from baseline (week 0) to week 26 is presented as ratio to baseline.
Time frame: Week 0, week 26
Change in Fasting Human Insulin - Ratio to Baseline
Change in fasting human insulin (measured in picomoles per liter \[pmol/L\]) from baseline (week 0) to week 26 is presented as ratio to baseline.
Time frame: Week 0, week 26
Change in Fasting Glucagon - Ratio to Baseline
Change in fasting glucagon (measured in picograms per milliliter \[pg/mL\]) from baseline (week 0) to week 26 is presented as ratio to baseline.
Time frame: Week 0, week 26
Change in HOMA-B (Beta Cell Function)- Ratio to Baseline
Change in HOMA-B (measured in %) from baseline (week 0) to week 26 is presented as ratio to baseline.
Time frame: Week 0, week 26
Change in Fasting Total Cholesterol - Ratio to Baseline
Change in fasting total cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Time frame: Week 0, week 26
Change in Fasting High Density Lipoprotein (HDL) Cholesterol- Ratio to Baseline
Change in fasting HDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline
Time frame: Week 0, week 26
Change in Fasting Low Density Lipoprotein (LDL) Cholesterol- Ratio to Baseline
Change in fasting LDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Time frame: Week 0, week 26
Change in Fasting Very Low-density Lipoprotein (VLDL) Cholesterol- Ratio to Baseline
Change in fasting VLDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline
Time frame: Week 0, week 26
Change in Fasting Triglycerides - Ratio to Baseline.
Change in fasting triglycerides (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Time frame: Week 0, week 26
Change in Fasting Free Fatty Acid - Ratio to Baseline
Change in fasting free fatty acid (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Time frame: Week 0, week 26
Number of Treatment-emergent Adverse Events (TEAE)
A TEAE was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. The observed rates of adverse events (AEs) per patient years of exposure (PYE) (number of AEs divided by PYE multiplied by 100) after 26 weeks are presented.
Time frame: Weeks 0-26
Number of Treatment Emergent Nocturnal Severe or BG Confirmed Hypoglycaemic Episodes.
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a PG value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Hypoglycaemic episodes were defined as nocturnal if the time of the onset was between 00:01 and 05.59 both inclusive. The number of episodes are represented as rates. The observed rates of episodes per PYE (number of episodes divided by PYE multiplied by 100) after 26 weeks of treatment are presented.
Time frame: Weeks 0-26
Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes.
Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. The number of episodes are represented as rates. The observed rates of episodes per PYE (number of episodes divided by PYE multiplied by 100) after 26 weeks of treatment are presented.
Time frame: Weeks 0-26
Number of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Hypoglycaemic episodes were defined as nocturnal if the time of the onset was between 00:01 and 05.59 both inclusive. The number of episodes are represented as rates. The observed rates of episodes per PYE (number of episodes divided by PYE multiplied by 100) after 26 weeks of treatment are presented.
Time frame: Weeks 0-26
Number of Treatment Emergent Hypoglycaemic Episodes According to ADA Definition
A hypoglycaemic episode was defined as treatment emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. The number of episodes are represented as rates. The observed rates of episodes (according to the ADA definition) per PYE (number of episodes divided by PYE multiplied by 100) after 26 weeks of treatment are presented.
Time frame: Weeks 0-26
Change in Physical Examination
Physical examination parameters are categorised as cardiovascular system; central and peripheral nervous system; gastrointestinal system including mouth; general appearance; head, ears, eyes, nose, throat, neck; lymph node palpation; musculoskeletal system; respiratory system; skin and thyroid gland. The number of participants assessed as normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS) at screening (week -2) and week 26 per each category is presented.
Time frame: Week -2, week 26
Eye Examination
Dilated fundoscopy or fundus photography was performed by the investigator at screening (week -2) and week 26. The results of the examination were interpreted for each eye (left and right) and are categorised as normal, abnormal NCS or abnormal CS. Number of participants in each category at screening (week -2) and week 26 is presented.
Time frame: Week -2, Week 26
Change in Electrocardiogram (ECG)
Electrocardiogram was assessed by the investigator as normal, abnormal NCS and abnormal CS. Number of participants at screening (week -2) and at week 26 is presented.
Time frame: Week -2, week 26
Change in Pulse
Change in pulse from baseline (week 0) after 26 weeks of treatment is presented
Time frame: Week 0, week 26
Change in Blood Pressure (Systolic and Diastolic Blood Pressure)
Change in blood pressure (systolic and diastolic blood pressure) from baseline (week 0) after 26 weeks of treatment is presented
Time frame: Week 0, week 26
Change in Biochemistry Parameters: Alkaline Phosphatase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatine Kinase, Amalyse, Lipase, Creatiine Kinase Serum
Change in alkaline phosphatase, ALT, AST, creatine kinase, amylase, lipase, creatine kinase serum from baseline (week 0) after 26 weeks of treatment is presented.
Time frame: Week 0, week 26
Change in Biochemistry Parameters (Albumin Serum, Total Protein)
Change in total protein, albumin serum from baseline (week 0) after 26 weeks of treatment is presented.
Time frame: Week 0, week 26
Change in Biochemistry Parameters: Calcium Serum (Total), Calcium Corrected Serum, Potassium Serum, Sodium Serum, Urea Serum
Change in calcium serum (total), calcium corrected serum, potassium serum, sodium serum, urea serum from baseline (week 0) after 26 weeks of treatment is presented.
Time frame: Week 0, week 26
Change in Biochemistry Parameters: Total Bilirubin Serum, Creatinine Serum
Change in total bilirubin serum, creatinine serum from baseline (week 0) after 26 weeks of treatment is presented.
Time frame: Week 0, week 26
Change in Haematological Parameter: Erythrocytes Blood
Change in erythrocyte blood from baseline (week 0) after 26 weeks of treatment is presented.
Time frame: Week 0, week 26
Change in Haematological Parameter: Haematocrits
Change in haematocrits from baseline (week 0) after 26 weeks of treatment is presented.
Time frame: Week 0, week 26
Change in Haemotological Parameter- Eosinophils
Change in eosinophils from baseline after 26 weeks of treatment is presented.
Time frame: Week 0, week 26
Change in Haematological Parameter - Neutrophils
Change in neutrophils from baseline (week 0) after 26 weeks of treatment is presented.
Time frame: Week 0, week 26
Change in Haematological Parameter: Basophils
Change in basophils from baseline (week 0) after 26 weeks of treatment is presented.
Time frame: Week 0, week 26
Change in Haemotological Parameter- Monocytes
Change in monocytes from baseline (week 0) after 26 weeks of treatment is presented
Time frame: Week 0, week 26
Change in Haematological Parameter - Lymphocytes
Change in lymphocytes from baseline (week 0) after 26 weeks of treatment is presented
Time frame: Week 0, week 26
Change in Haematology: Haemoglobin Blood
Change in haemoglobin from baseline (week 0) after 26 weeks of treatment is presented.
Time frame: Week 0, week 26
Change in Haematologcal Parameter: Leukocytes
Change in leukocytes from baseline (week 0) after 26 weeks of treatment
Time frame: Week 0, week 26
Change in Haematological Parameter: Thrombocytes
Change in thrombocytes from baseline (week 0) after 26 weeks of treatment
Time frame: Week 0, week 26
Change in Calcitonin
Calcitonin levels were measured and were categorised as low, normal or high in relation to reference range (8.31- 14.3 picogram/milliliter \[pg/mL\]). Number of participants in each category at baseline (week 0) and week 26 are presented.
Time frame: Week 0, week 26
Urinalysis (Protein, Glucose, Erythrocytes and Ketones)
The urinalysis assessment was the measurements of protein, glucose, erythrocytes and ketones in urine at baseline (week 0) and week 26 and categorised as negative, trace and positive. Number of participants in each category at week 0 and week 26 is presented.
Time frame: Week 0, week 26
Occurence of Anti-insulin Degludec Specific Antibodies
This outcome measure is only applicable for the insulin degludec/liraglutide arm and insulin degludec arm. Serum samples were analysed for the presence of anti-insulin degludec specific antibodies. Results at week 27 are presented as percentage of bound radioactive-labelled insulin (B) /total radioactive-labelled insulin added to the samples (T).
Time frame: Week 27
Occurence of Antibodies Cross-reacting to Human Insulin
This outcome measure is only applicable for the insulin degludec/liraglutide arm and insulin degludec arm. Serum samples were analysed for the presence of cross-reacting antibodies to human insulin. Results at week 27 are presented as percentage of bound radioactive-labelled insulin (B) /total radioactive-labelled insulin added to the samples (T).
Time frame: Week 27
Occurence of Total Insulin Antibodies
This outcome measure is only applicable for the Insulin degludec/liraglutide arm and Insulin degludec arm. Serum samples were analysed for the presence of antobodies to human insulin. Results at week 27 are presented as percentage of bound radioactive-labelled insulin (B) /total radioactive-labelled insulin added to the samples (T).
Time frame: Week 27
Occurence of Anti-liraglutide Antibodies
This outcome measure is applicable for the Insulin degludec/liraglutide arm and the liraglutide arm. Serum samples were analysed for the presence of anti-liraglutide antibodies. Number of participants who were assessed for anti-liraglutide antibodies at week 27 are presented.
Time frame: Week 27
Occurence of Antibodies Cross-reacting to Native Glucagon-like Peptide (GLP-1)
This outcome measure is applicable to the Insulin degludec/liraglutide arm and the liraglutide arm. Serum samples were analysed for the presence of cross-reacting antibodies to native GLP-1. Number of participants who measured with anti-liraglutide antibodies cross reacting native GLP-1 at week 27 are presented.
Time frame: Week 27
Occurence of Neutralising Liraglutide Antibodies
This outcome measure is only applicable for the Insulin degludec/liraglutide arm and liraglutide arm. Neutralising antibodies were assessed when the corresponding anti-Liraglutide antibody were positive at week 27. Number of participants who measured with neutralising liraglutide antibodies at week 27 are presented.
Time frame: Week 27
Occurence of Neutralising Antibodies Cross-reacting to Native GLP-1
This outcome measure is only applicable for the Insulin degludec/liraglutide arm and liraglutide arm. Cross reacting antibodies were assessed when anti-liraglutide antibody was positive. Number of participants who measured with neutralising liraglutide antibodies cross-reacting to native GLP-1 at week 27 are presented.
Time frame: Week 27
Serum Concentrations of Insulin Degludec
This outcome measure is applicable for Insulin degludec and Insulin degludec/liraglutide arms. Serum samples from the Insulin degludec/liraglutide and Insulin degludec arms were assayed using population PK analysis. The maximum serum concentrations (Cmax) are summarised for the two arms.
Time frame: Week 0, week 26
Plasma Concentration of Liraglutide
This outcome measure is for Insulin degludec/liraglutide and liraglutide arms. Serum samples from the Insulin degludec/liraglutide and liraglutide arms were assayed using population PK analysis. The Cmax are summarised for the two arms.
Time frame: Week 0, week 26
The trial was conducted at 38 sites in China mainland.
| Milestone | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Started | 361 | 179 | 180 |
| Full analysis set (fas) | 361 | 179 | 180 |
| Safety analysis set (sas) | 358 | 175 | 180 |
| Exposed | 358 | 175 | 180 |
| Completed | 341 | 167 | 151 |
| Not completed | 20 | 12 | 29 |
| Withdrew: Adverse event | 5 | 1 | 15 |
| Withdrew: Protocol violation | 3 | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 4 |
| Withdrew: Pregnancy | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 10 | 8 | 8 |
| Withdrew: Severe hypoglycaemic episode | 0 | 0 | 1 |
| Withdrew: Non-compliance towards treatment | 2 | 0 | 0 |
Change in HbA1c from baseline (week 0) after 26 weeks of treatment is presented.
| Percentage points of HbA1c | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in HbA1c | -1.71 ± 0.88 | -1.20 ± 0.99 | -1.16 ± 0.89 |
Change in body weight from baseline (week 0) after 26 weeks of treatment is presented.
| Kilogram (Kg) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Body Weight | 0.2 ± 2.7 | 1.3 ± 2.7 | -2.5 ± 2.7 |
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification (requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or blood glucose (BG) confirmed by a plasma glucose (PG) value \< 3.1 millimoles per liter (mmol/L) with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. The number of episodes are represented as rates. The observed rates of treatment-emergent severe or BG confirmed hypoglycaemic episodes per patient years of exposure (PYE) (number of episodes divided by PYE multiplied by 100) during 26 weeks of treatment are presented.
| (Number of episodes/PYE)*100 | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Number of Treatment Emergent Severe or BG Confirmed Hypoglycaemic Episodes | 23.94 | 17.01 | 3.60 |
The actual daily total insulin dose after 26 weeks of treatment is presented. This outcome measure is only applicable for Insulin degludec/liraglutide and Insulin degludec treatment arms.
| Units of insulin (U) | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Insulin Dose | 24.8 ± 11.9 | 30.1 ± 14.4 |
Number of participants who achieved ADA HbA1c target (HbA1c \< 7.0%) (yes/no) after 26 weeks of treatment are presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Yes | 272 | 83 | 80 |
| No | 69 | 84 | 71 |
Number of participants who achieved IDF HbA1c target (HbA1c ≤ 6.5%) (yes/no) after 26 weeks of treatment are presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Yes | 201 | 48 | 41 |
| No | 140 | 119 | 110 |
Number of participants who achieved ADA HbA1c target (HbA1c \< 7.0%) (yes/no) and change from baseline in body weight below or equal to zero after 26 weeks are presented. Missing values are imputed by LOCF.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Yes | 147 | 34 | 74 |
| No | 214 | 145 | 106 |
Number of participants who achieved IDF HbA1c target (HbA1c ≤ 6.5%) (yes/no) and change from baseline in body weight below or equal to zero after 26 weeks are presented. Missing values are imputed by LOCF.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Yes | 111 | 21 | 37 |
| No | 250 | 158 | 143 |
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of participants who achieved ADA HbA1c target (HbA1c \<7.0%) (yes/no) after 26 weeks of treatment and without severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment are presented. Missing values are imputed by LOCF.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Yes | 265 | 80 | 84 |
| No | 96 | 99 | 96 |
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a PG value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of participants who achieved IDF HbA1c target (HbA1c ≤ 6.5%) (yes/no) after 26 weeks of treatment and without severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment are presented. Missing values are imputed by LOCF.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Yes | 195 | 46 | 43 |
| No | 166 | 133 | 137 |
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a PG value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of participants who achieved ADA HbA1c target (HbA1c \< 7.0%) (yes/no) after 26 weeks of treatment without severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment and with change from baseline in body weight below or equal to zero are presented. Missing values are imputed by LOCF.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Yes | 136 | 33 | 72 |
| No | 225 | 146 | 108 |
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a PG value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of participants who achieved IDF HbA1c target (HbA1c ≤ 6.5%) (yes/no) after 26 weeks of treatment without severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment and with change from baseline in body weight below or equal to zero are presented. Missing values are imputed by LOCF.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Yes | 103 | 21 | 36 |
| No | 258 | 158 | 144 |
Change from baseline (week 0) in FPG after 26 weeks of treatment is presented.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Fasting Plasma Glucose (FPG) | -3.64 ± 2.27 | -3.45 ± 2.34 | -1.86 ± 2.11 |
Change from baseline (week 0) in waist circumferance after 26 weeks of treatment is presented.
| Centimeters (cm) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Waist Circumferance | -0.3 ± 3.4 | 1.2 ± 4.2 | -2.6 ± 3.8 |
Participants measured their PG levels using blood glucose meters at 9 time points (before breakfast, 90 minutes after the start of breakfast, before lunch, 90 minutes after the start of lunch, before dinner, 90 minutes after the start of dinner, at bedtime, at 4 am, before breakfast the following day). 9-point SMPG values at 26 weeks of treatment are presented.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Before breakfast | 5.41 ± 1.07 | 5.66 ± 1.20 | 6.89 ± 1.37 |
| 90 minutes after the start of breakfast | 8.97 ± 2.48 | 9.85 ± 2.73 | 10.04 ± 2.81 |
| Before lunch | 6.31 ± 1.80 | 7.10 ± 2.35 | 7.48 ± 2.14 |
| 90 minutes after the start of the lunch | 8.87 ± 2.15 | 10.18 ± 2.81 | 9.54 ± 2.43 |
| Before dinner | 6.52 ± 1.77 | 7.39 ± 2.23 | 7.50 ± 2.11 |
| 90 minutes after start of the dinner | 9.33 ± 2.40 | 10.27 ± 2.68 | 9.45 ± 2.13 |
| At bedtime | 7.99 ± 2.28 | 8.86 ± 2.38 | 8.49 ± 2.26 |
| At 4:00 am | 5.60 ± 1.26 | 6.12 ± 1.75 | 6.86 ± 1.60 |
| Before breakfast the following day | 5.35 ± 0.96 | 5.47 ± 1.07 | 6.81 ± 1.47 |
Participants measured their PG levels using blood glucose meters at 9 time points (before breakfast, 90 minutes after the start of breakfast, before lunch, 90 minutes after the start of lunch, before dinner, 90 minutes after the start of dinner, at bedtime, at 4 am, before breakfast the following day). The mean of profile is defined as the area under the profile divided by measurement time and is calculated using the trapezoidal method. Change in mean of the 9-point SMPG profile from baseline (week 0) to week 26 is presented.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Mean of 9-point SMPG Profile | -3.17 ± 2.16 | -2.47 ± 2.14 | -2.13 ± 2.02 |
Participants measured their PG levels using blood glucose meters at 9 time points (before breakfast, 90 minutes after the start of breakfast, before lunch, 90 minutes after the start of lunch, before dinner, 90 minutes after the start of dinner, at bedtime, at 4 am, before breakfast the following day). Post-prandial SMPG increments from before meal to 90 minutes after for breakfast, lunch and dinner were calculated. The mean increment over all meals was derived as the mean of all available meal increments. Change from baseline (week 0) in post-prandial SMPG increments for all meals after 26 weeks of treatment is presented.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Mean Post-prandial Plasma Glucose (PG) Increments | -0.20 ± 2.40 | 0.09 ± 2.40 | -0.54 ± 2.57 |
Change in fasting C-peptide (measured in nanomoles per liter \[nmol/L\]) from baseline (week 0) to week 26 is presented as ratio to baseline.
| Ratio of fasting C-peptide | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Fasting C-peptide - Ratio to Baseline | 0.54 ± 52.8 | 0.38 ± 68.5 | 0.98 ± 37.6 |
Change in fasting human insulin (measured in picomoles per liter \[pmol/L\]) from baseline (week 0) to week 26 is presented as ratio to baseline.
| Ratio of fasting human insulin | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Fasting Human Insulin - Ratio to Baseline | 0.53 ± 71.7 | 0.38 ± 77.6 | 1.04 ± 53.3 |
Change in fasting glucagon (measured in picograms per milliliter \[pg/mL\]) from baseline (week 0) to week 26 is presented as ratio to baseline.
| Ratio of fasting glucagon | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Fasting Glucagon - Ratio to Baseline | 0.90 ± 76.6 | 0.95 ± 56.4 | 0.98 ± 75.9 |
Change in HOMA-B (measured in %) from baseline (week 0) to week 26 is presented as ratio to baseline.
| Ratio of HOMA-B (beta cell function) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in HOMA-B (Beta Cell Function)- Ratio to Baseline | 1.38 ± 77.3 | 0.94 ± 77.4 | 1.53 ± 63.8 |
Change in fasting total cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
| Ratio of fasting total cholesterol | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Fasting Total Cholesterol - Ratio to Baseline | 0.94 ± 19.1 | 0.99 ± 16.8 | 0.97 ± 17.7 |
Change in fasting HDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline
| Ratio of fasting HDL cholesterol | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Fasting High Density Lipoprotein (HDL) Cholesterol- Ratio to Baseline | 1.01 ± 14.7 | 1.02 ± 15.7 | 1.03 ± 14.8 |
Change in fasting LDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
| Ratio of fasting LDL cholesterol | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Fasting Low Density Lipoprotein (LDL) Cholesterol- Ratio to Baseline | 0.92 ± 34.2 | 1.01 ± 36.2 | 0.96 ± 34.4 |
Change in fasting VLDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline
| Ratio of fasting VLDL cholesterol | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Fasting Very Low-density Lipoprotein (VLDL) Cholesterol- Ratio to Baseline | 0.90 ± 49.9 | 0.84 ± 47.2 | 0.92 ± 38.6 |
Change in fasting triglycerides (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
| Ratio of fasting triglycerides | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Fasting Triglycerides - Ratio to Baseline. | 0.88 ± 54.4 | 0.82 ± 50.5 | 0.90 ± 45.2 |
Change in fasting free fatty acid (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
| Ratio of fasting free fatty acid | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Fasting Free Fatty Acid - Ratio to Baseline | 0.55 ± 69.9 | 0.48 ± 76.5 | 0.80 ± 69.3 |
A TEAE was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. The observed rates of adverse events (AEs) per patient years of exposure (PYE) (number of AEs divided by PYE multiplied by 100) after 26 weeks are presented.
| (Number of AEs/PYE)*100 | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Number of Treatment-emergent Adverse Events (TEAE) | 410.82 | 306.19 | 541.00 |
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a PG value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Hypoglycaemic episodes were defined as nocturnal if the time of the onset was between 00:01 and 05.59 both inclusive. The number of episodes are represented as rates. The observed rates of episodes per PYE (number of episodes divided by PYE multiplied by 100) after 26 weeks of treatment are presented.
| (Number of episodes/PYE)*100 | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Number of Treatment Emergent Nocturnal Severe or BG Confirmed Hypoglycaemic Episodes. | 4.45 | 4.54 | — |
Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. The number of episodes are represented as rates. The observed rates of episodes per PYE (number of episodes divided by PYE multiplied by 100) after 26 weeks of treatment are presented.
| (Number of episodes/PYE)*100 | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes. | 15.03 | 9.07 | 1.20 |
Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Hypoglycaemic episodes were defined as nocturnal if the time of the onset was between 00:01 and 05.59 both inclusive. The number of episodes are represented as rates. The observed rates of episodes per PYE (number of episodes divided by PYE multiplied by 100) after 26 weeks of treatment are presented.
| (Number of episodes/PYE)*100 | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Number of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes | 2.78 | 3.40 | — |
A hypoglycaemic episode was defined as treatment emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. The number of episodes are represented as rates. The observed rates of episodes (according to the ADA definition) per PYE (number of episodes divided by PYE multiplied by 100) after 26 weeks of treatment are presented.
| (Number of episodes/PYE)*100 | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Number of Treatment Emergent Hypoglycaemic Episodes According to ADA Definition | 668.55 | 746.20 | 37.19 |
Physical examination parameters are categorised as cardiovascular system; central and peripheral nervous system; gastrointestinal system including mouth; general appearance; head, ears, eyes, nose, throat, neck; lymph node palpation; musculoskeletal system; respiratory system; skin and thyroid gland. The number of participants assessed as normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS) at screening (week -2) and week 26 per each category is presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Week -2: Cardiovascular system — Normal | 353 | 173 | 180 |
| Week -2: Cardiovascular system — Abnormal, NCS | 2 | 2 | 0 |
| Week -2: Cardiovascular system — Abnormal CS | 3 | 0 | 0 |
| Week 26: Cardiovascular system — Normal | 336 | 166 | 151 |
| Week 26: Cardiovascular system — Abnormal, NCS | 3 | 1 | 0 |
| Week 26: Cardiovascular system — Abnormal CS | 2 | 0 | 0 |
| Week -2: Central and peripheral nervous system — Normal | 355 | 172 | 179 |
| Week -2: Central and peripheral nervous system — Abnormal, NCS | 1 | 0 | 0 |
| Week -2: Central and peripheral nervous system — Abnormal CS | 2 | 3 | 1 |
| Week 26: Central and peripheral nervous system — Normal | 338 | 164 | 150 |
| Week 26: Central and peripheral nervous system — Abnormal, NCS | 1 | 0 | 0 |
| Week 26: Central and peripheral nervous system — Abnormal CS | 2 | 3 | 1 |
| Week -2: Gastrointestinal system including mouth — Normal | 355 | 174 | 179 |
| Week -2: Gastrointestinal system including mouth — Abnormal, NCS | 3 | 1 | 1 |
| Week -2: Gastrointestinal system including mouth — Abnormal CS | 0 | 0 | 0 |
| Week 26: Gastrointestinal system including mouth — Normal | 339 | 166 | 150 |
| Week 26: Gastrointestinal system including mouth — Abnormal, NCS | 2 | 1 | 1 |
| Week 26: Gastrointestinal system including mouth — Abnormal CS | 0 | 0 | 0 |
| Week -2: General appearance — Normal | 351 | 169 | 177 |
| Week -2: General appearance — Abnormal, NCS | 3 | 2 | 1 |
| Week -2: General appearance — Abnormal CS | 4 | 4 | 2 |
| Week 26: General appearance — Normal | 336 | 161 | 150 |
| Week 26: General appearance — Abnormal, NCS | 2 | 2 | 0 |
| Week 26: General appearance — Abnormal CS | 3 | 4 | 1 |
| Week -2: Head, ears, eyes, nose, throat, neck — Normal | 348 | 170 | 175 |
| Week -2: Head, ears, eyes, nose, throat, neck — Abnormal, NCS | 6 | 4 | 3 |
| Week -2: Head, ears, eyes, nose, throat, neck — Abnormal CS | 4 | 1 | 2 |
| Week 26: Head, ears, eyes, nose, throat, neck — Normal | 332 | 164 | 150 |
| Week 26: Head, ears, eyes, nose, throat, neck — Abnormal, NCS | 6 | 3 | 1 |
| Week 26: Head, ears, eyes, nose, throat, neck — Abnormal CS | 3 | 0 | 0 |
| Week -2: Lymph node palpation — Normal | 357 | 174 | 180 |
| Week -2: Lymph node palpation — Abnormal, NCS | 0 | 0 | 0 |
| Week -2: Lymph node palpation — Abnormal CS | 1 | 1 | 0 |
| Week 26: Lymph node palpation — Normal | 340 | 166 | 151 |
| Week 26: Lymph node palpation — Abnormal, NCS | 0 | 0 | 0 |
| Week 26: Lymph node palpation — Abnormal CS | 1 | 1 | 0 |
| Week -2: Musculoskeletal system — Normal | 353 | 172 | 177 |
| Week -2: Musculoskeletal system — Abnormal, NCS | 2 | 2 | 0 |
| Week -2: Musculoskeletal system — Abnormal CS | 3 | 1 | 3 |
| Week 26: Musculoskeletal system — Normal | 332 | 165 | 149 |
| Week 26: Musculoskeletal system — Abnormal, NCS | 2 | 1 | 0 |
| Week 26: Musculoskeletal system — Abnormal CS | 7 | 1 | 2 |
| Week-2: Respiratory system — Normal | 358 | 175 | 180 |
| Week-2: Respiratory system — Abnormal, NCS | 0 | 0 | 0 |
| Week-2: Respiratory system — Abnormal CS | 0 | 0 | 0 |
| Week 26: Respiratory system — Normal | 341 | 167 | 151 |
| Week 26: Respiratory system — Abnormal, NCS | 0 | 0 | 0 |
| Week 26: Respiratory system — Abnormal CS | 0 | 0 | 0 |
| week -2: Skin — Normal | 312 | 152 | 156 |
| week -2: Skin — Abnormal, NCS | 37 | 20 | 20 |
| week -2: Skin — Abnormal CS | 9 | 3 | 4 |
| Week 26: Skin — Normal | 297 | 146 | 134 |
| Week 26: Skin — Abnormal, NCS | 36 | 19 | 15 |
| Week 26: Skin — Abnormal CS | 8 | 2 | 2 |
| Week -2: Thyroid gland — Normal | 348 | 171 | 179 |
| Week -2: Thyroid gland — Abnormal, NCS | 5 | 1 | 1 |
| Week -2: Thyroid gland — Abnormal CS | 5 | 3 | 0 |
| Week 26: Thyroid gland — Normal | 334 | 163 | 151 |
| Week 26: Thyroid gland — Abnormal, NCS | 3 | 2 | 0 |
| Week 26: Thyroid gland — Abnormal CS | 4 | 2 | 0 |
Dilated fundoscopy or fundus photography was performed by the investigator at screening (week -2) and week 26. The results of the examination were interpreted for each eye (left and right) and are categorised as normal, abnormal NCS or abnormal CS. Number of participants in each category at screening (week -2) and week 26 is presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Week -2: Left eye — Normal | 222 | 109 | 110 |
| Week -2: Left eye — Abnormal, NCS | 45 | 14 | 20 |
| Week -2: Left eye — Abnormal, CS | 91 | 52 | 50 |
| Week 26: Left eye — Normal | 217 | 99 | 100 |
| Week 26: Left eye — Abnormal, NCS | 39 | 20 | 13 |
| Week 26: Left eye — Abnormal, CS | 85 | 48 | 38 |
| Week -2: Right eye — Normal | 230 | 112 | 111 |
| Week -2: Right eye — Abnormal, NCS | 42 | 16 | 22 |
| Week -2: Right eye — Abnormal, CS | 86 | 47 | 47 |
| Week 26: Right eye — Normal | 217 | 103 | 96 |
| Week 26: Right eye — Abnormal, NCS | 40 | 23 | 15 |
| Week 26: Right eye — Abnormal, CS | 84 | 41 | 40 |
Electrocardiogram was assessed by the investigator as normal, abnormal NCS and abnormal CS. Number of participants at screening (week -2) and at week 26 is presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Week -2 — Normal | 223 | 109 | 108 |
| Week -2 — Abnormal, NCS | 94 | 46 | 52 |
| Week -2 — Abnormal CS | 41 | 20 | 20 |
| Week 26 — Normal | 227 | 108 | 87 |
| Week 26 — Abnormal, NCS | 76 | 47 | 40 |
| Week 26 — Abnormal CS | 38 | 12 | 24 |
Change in pulse from baseline (week 0) after 26 weeks of treatment is presented
| Beats per minuts (beats/min) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Pulse | 4.6 ± 8.6 | -0.1 ± 8.6 | 4.9 ± 9.7 |
Change in blood pressure (systolic and diastolic blood pressure) from baseline (week 0) after 26 weeks of treatment is presented
| Millimeters of mercury (mmHg) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Systolic blood pressure | -3.5 ± 12.7 | -1.2 ± 11.7 | -3.3 ± 13.8 |
| Distolic blood pressure | -0.4 ± 8.3 | -0.7 ± 8.1 | 0.0 ± 8.4 |
Change in alkaline phosphatase, ALT, AST, creatine kinase, amylase, lipase, creatine kinase serum from baseline (week 0) after 26 weeks of treatment is presented.
| Units per liter (U/L) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Alkaline phosphatase | -2.0 ± 14.85 | -2.29 ± 11.49 | -0.48 ± 14.11 |
| ALT | -4.63 ± 13.06 | -6.17 ± 13.54 | -2.81 ± 16.97 |
| AST | -1.31 ± 7.94 | -2.65 ± 8.40 | -0.99 ± 9.64 |
| Creatine kinase | 10.67 ± 100.87 | 15.37 ± 52.99 | 0.52 ± 56.20 |
| Amylase | 9.84 ± 36.73 | 5.09 ± 14.68 | 5.68 ± 13.70 |
| Lipase | 16.13 ± 101.19 | -1.87 ± 15.64 | 14.11 ± 19.76 |
Change in total protein, albumin serum from baseline (week 0) after 26 weeks of treatment is presented.
| grams per decileter (g/dL) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Albumin serum | -0.05 ± 0.28 | -0.09 ± 0.26 | 0.04 ± 0.26 |
| Total protein | -0.08 ± 0.42 | -0.08 ± 0.39 | -0.01 ± 0.39 |
Change in calcium serum (total), calcium corrected serum, potassium serum, sodium serum, urea serum from baseline (week 0) after 26 weeks of treatment is presented.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Calcium serum (total) | -0.01 ± 0.10 | -0.02 ± 0.10 | -0.00 ± 0.09 |
| Calcium corrected serum | -0.00 ± 0.08 | -0.00 ± 0.08 | -0.01 ± 0.07 |
| Sodium serum | 1.21 ± 2.09 | 0.98 ± 2.37 | 0.32 ± 2.12 |
| Urea serum | 0.05 ± 0.57 | 0.03 ± 0.53 | 0.16 ± 0.67 |
| Potassium serum | -0.04 ± 0.34 | -0.09 ± 0.39 | -0.04 ± 0.34 |
Change in total bilirubin serum, creatinine serum from baseline (week 0) after 26 weeks of treatment is presented.
| micromoles per liter (umol/L) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Total bilirubin | -0.78 ± 3.35 | -0.55 ± 4.52 | -1.16 ± 3.92 |
| creatinine serum | 1.02 ± 8.41 | 1.36 ± 7.92 | -0.60 ± 7.89 |
Change in erythrocyte blood from baseline (week 0) after 26 weeks of treatment is presented.
| 10^12 cells per liter (10^12/L) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Haematological Parameter: Erythrocytes Blood | -0.05 ± 0.27 | -0.00 ± 0.27 | -0.05 ± 0.25 |
Change in haematocrits from baseline (week 0) after 26 weeks of treatment is presented.
| Percentage points (%) of red blood cells | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Haematological Parameter: Haematocrits | -0.56 ± 2.65 | -0.49 ± 2.69 | -0.42 ± 2.57 |
Change in eosinophils from baseline after 26 weeks of treatment is presented.
| % of eosinophils | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Haemotological Parameter- Eosinophils | -0.06 ± 1.90 | 0.19 ± 1.73 | 0.11 ± 1.94 |
Change in neutrophils from baseline (week 0) after 26 weeks of treatment is presented.
| % of neutrophils | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Haematological Parameter - Neutrophils | 0.57 ± 6.46 | 0.18 ± 7.70 | -0.53 ± 7.05 |
Change in basophils from baseline (week 0) after 26 weeks of treatment is presented.
| % of basophils | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Haematological Parameter: Basophils | -0.02 ± 0.29 | -0.01 ± 0.28 | -0.03 ± 0.26 |
Change in monocytes from baseline (week 0) after 26 weeks of treatment is presented
| % of monocytes | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Haemotological Parameter- Monocytes | -0.03 ± 1.92 | 0.01 ± 1.85 | 0.05 ± 2.13 |
Change in lymphocytes from baseline (week 0) after 26 weeks of treatment is presented
| % of lymphocytes | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Haematological Parameter - Lymphocytes | -0.46 ± 6.04 | -0.38 ± 7.12 | 0.40 ± 6.11 |
Change in haemoglobin from baseline (week 0) after 26 weeks of treatment is presented.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Haematology: Haemoglobin Blood | -0.10 ± 0.53 | -0.06 ± 0.48 | -0.05 ± 0.47 |
Change in leukocytes from baseline (week 0) after 26 weeks of treatment
| 10^9 cells per liter (10^9/L) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Haematologcal Parameter: Leukocytes | 0.25 ± 1.18 | 0.23 ± 1.41 | -0.01 ± 1.14 |
Change in thrombocytes from baseline (week 0) after 26 weeks of treatment
| 10^9 cells per liter (10^9/L) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Change in Haematological Parameter: Thrombocytes | 8.19 ± 28.02 | 8.32 ± 34.48 | 4.32 ± 33.39 |
Calcitonin levels were measured and were categorised as low, normal or high in relation to reference range (8.31- 14.3 picogram/milliliter \[pg/mL\]). Number of participants in each category at baseline (week 0) and week 26 are presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Week 0 — Low | 0 | 0 | 0 |
| Week 0 — Normal | 351 | 172 | 178 |
| Week 0 — High | 7 | 3 | 2 |
| Week 26 — Low | 0 | 0 | 0 |
| Week 26 — Normal | 334 | 165 | 147 |
| Week 26 — High | 6 | 2 | 3 |
The urinalysis assessment was the measurements of protein, glucose, erythrocytes and ketones in urine at baseline (week 0) and week 26 and categorised as negative, trace and positive. Number of participants in each category at week 0 and week 26 is presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Week 0: Erythrocytes — Negative | 299 | 153 | 156 |
| Week 0: Erythrocytes — Trace | 36 | 16 | 16 |
| Week 0: Erythrocytes — Positive | 22 | 6 | 8 |
| Week 26: Erythrocytes — Negative | 297 | 146 | 136 |
| Week 26: Erythrocytes — Trace | 28 | 16 | 11 |
| Week 26: Erythrocytes — Positive | 14 | 5 | 4 |
| Week 0: Glucose — Negative | 253 | 119 | 123 |
| Week 0: Glucose — Trace | 35 | 19 | 18 |
| Week 0: Glucose — Positive | 69 | 37 | 39 |
| Week 26: Glucose — Negative | 322 | 157 | 131 |
| Week 26: Glucose — Trace | 11 | 3 | 5 |
| Week 26: Glucose — Positive | 6 | 7 | 15 |
| Week 0: Ketones — Negative | 325 | 152 | 167 |
| Week 0: Ketones — Trace | 25 | 20 | 11 |
| Week 0: Ketones — Positive | 7 | 3 | 2 |
| Week 26: Ketones — Negative | 334 | 163 | 141 |
| Week 26: Ketones — Trace | 4 | 3 | 10 |
| Week 26: Ketones — Positive | 1 | 1 | 0 |
| Week 0: Protein — Negative | 216 | 104 | 116 |
| Week 0: Protein — Trace | 86 | 40 | 37 |
| Week 0: Protein — Positive | 55 | 31 | 27 |
| Week 26: Protein — Negative | 254 | 120 | 105 |
| Week 26: Protein — Trace | 58 | 26 | 28 |
| Week 26: Protein — Positive | 27 | 21 | 18 |
This outcome measure is only applicable for the insulin degludec/liraglutide arm and insulin degludec arm. Serum samples were analysed for the presence of anti-insulin degludec specific antibodies. Results at week 27 are presented as percentage of bound radioactive-labelled insulin (B) /total radioactive-labelled insulin added to the samples (T).
| %B/T | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Occurence of Anti-insulin Degludec Specific Antibodies | 0.22 ± 1.02 | 0.12 ± 0.79 |
This outcome measure is only applicable for the insulin degludec/liraglutide arm and insulin degludec arm. Serum samples were analysed for the presence of cross-reacting antibodies to human insulin. Results at week 27 are presented as percentage of bound radioactive-labelled insulin (B) /total radioactive-labelled insulin added to the samples (T).
| %B/T | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Occurence of Antibodies Cross-reacting to Human Insulin | 6.61 ± 15.00 | 2.99 ± 10.89 |
This outcome measure is only applicable for the Insulin degludec/liraglutide arm and Insulin degludec arm. Serum samples were analysed for the presence of antobodies to human insulin. Results at week 27 are presented as percentage of bound radioactive-labelled insulin (B) /total radioactive-labelled insulin added to the samples (T).
| %B/T | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Occurence of Total Insulin Antibodies | 6.83 ± 15.78 | 3.11 ± 11.42 |
This outcome measure is applicable for the Insulin degludec/liraglutide arm and the liraglutide arm. Serum samples were analysed for the presence of anti-liraglutide antibodies. Number of participants who were assessed for anti-liraglutide antibodies at week 27 are presented.
| Participants | Insulin Degludec/Liraglutide | Liraglutide |
|---|---|---|
| Yes | 45 | 40 |
| No | 287 | 120 |
This outcome measure is applicable to the Insulin degludec/liraglutide arm and the liraglutide arm. Serum samples were analysed for the presence of cross-reacting antibodies to native GLP-1. Number of participants who measured with anti-liraglutide antibodies cross reacting native GLP-1 at week 27 are presented.
| Participants | Insulin Degludec/Liraglutide | Liraglutide |
|---|---|---|
| Occurence of Antibodies Cross-reacting to Native Glucagon-like Peptide (GLP-1) | 6 | 3 |
This outcome measure is only applicable for the Insulin degludec/liraglutide arm and liraglutide arm. Neutralising antibodies were assessed when the corresponding anti-Liraglutide antibody were positive at week 27. Number of participants who measured with neutralising liraglutide antibodies at week 27 are presented.
| Participants | Insulin Degludec/Liraglutide | Liraglutide |
|---|---|---|
| Occurence of Neutralising Liraglutide Antibodies | 9 | 8 |
This outcome measure is only applicable for the Insulin degludec/liraglutide arm and liraglutide arm. Cross reacting antibodies were assessed when anti-liraglutide antibody was positive. Number of participants who measured with neutralising liraglutide antibodies cross-reacting to native GLP-1 at week 27 are presented.
| Participants | Insulin Degludec/Liraglutide | Liraglutide |
|---|---|---|
| Occurence of Neutralising Antibodies Cross-reacting to Native GLP-1 | 0 | 0 |
This outcome measure is applicable for Insulin degludec and Insulin degludec/liraglutide arms. Serum samples from the Insulin degludec/liraglutide and Insulin degludec arms were assayed using population PK analysis. The maximum serum concentrations (Cmax) are summarised for the two arms.
| pmol/L | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Serum Concentrations of Insulin Degludec | 3583 ± 55.9 | 4133 ± 52.8 |
This outcome measure is for Insulin degludec/liraglutide and liraglutide arms. Serum samples from the Insulin degludec/liraglutide and liraglutide arms were assayed using population PK analysis. The Cmax are summarised for the two arms.
| pmol/L | Insulin Degludec/Liraglutide | Liraglutide |
|---|---|---|
| Plasma Concentration of Liraglutide | 9963 ± 50.4 | 21602 ± 37 |
Collected over Weeks 0-30. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Degludec/Liraglutide | 0/358 (0%) | 14/358 (3.9%) | 161/358 (45%) |
| Insulin Degludec | 0/175 (0%) | 7/175 (4%) | 55/175 (31.4%) |
| Liraglutide | 0/180 (0%) | 14/180 (7.8%) | 98/180 (54.4%) |
| Event | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Cerebral infarctionNervous system disorders | 1/358 | 0/175 | 3/180 |
| Angina unstableCardiac disorders | 2/358 | 1/175 | 0/180 |
| Cataract operationSurgical and medical procedures | 0/358 | 1/175 | 0/180 |
| Chronic gastritisGastrointestinal disorders | 0/358 | 1/175 | 0/180 |
| Deafness neurosensoryEar and labyrinth disorders | 0/358 | 1/175 | 0/180 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 0/358 | 1/175 | 0/180 |
| Dupuytren's contractureMusculoskeletal and connective tissue disorders | 0/358 | 1/175 | 0/180 |
| Foot fractureInjury, poisoning and procedural complications | 0/358 | 1/175 | 0/180 |
| TinnitusEar and labyrinth disorders | 0/358 | 1/175 | 0/180 |
| Appendicitis perforatedInfections and infestations | 0/358 | 0/175 | 1/180 |
| Event | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 66/358 | 31/175 | 18/180 |
| Decreased appetiteMetabolism and nutrition disorders | 13/358 | 2/175 | 26/180 |
| DiarrhoeaGastrointestinal disorders | 23/358 | 3/175 | 26/180 |
| Lipase increasedInvestigations | 27/358 | 5/175 | 22/180 |
| NauseaGastrointestinal disorders | 14/358 | 1/175 | 21/180 |
| Diabetic retinopathyEye disorders | 28/358 | 6/175 | 10/180 |
| Gastrointestinal disorderGastrointestinal disorders | 1/358 | 0/175 | 10/180 |
| HyperlipidaemiaMetabolism and nutrition disorders | 16/358 | 6/175 | 10/180 |
| NasopharyngitisInfections and infestations | 16/358 | 9/175 | 5/180 |
| Abdominal discomfortGastrointestinal disorders | 1/358 | 0/175 | 9/180 |
FAS included all randomised participants.
| Age, Continuous(years) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide | Total |
|---|---|---|---|---|
| Mean | 54.5 ± 10.3 | 55.7 ± 10.2 | 54.1 ± 10.2 | 54.7 ± 10.3 |
| Sex/Gender, Customized(Participants) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide | Total |
|---|---|---|---|---|
| Female | 142 | 79 | 72 | 293 |
| Male | 219 | 100 | 108 | 427 |
| Ethnicity (NIH/OMB)(Participants) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 361 | 179 | 180 | 720 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 361 | 179 | 180 | 720 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Glycosylated haemoglobin (HbA1c)(Percentage points of HbA1c) | Insulin Degludec/Liraglutide | Insulin Degludec | Liraglutide | Total |
|---|---|---|---|---|
| Mean | 8.20 ± 0.83 | 8.31 ± 0.84 | 8.21 ± 0.77 | 8.23 ± 0.82 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from May 2017 to primary completion in Jun 2019, 24 months.
Results were first posted in Jul 2020, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 24 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Liraglutide